Association Between Chlamydia pneumoniae Antibodies and Intimal Calcification in Femoral Arteries of Nondiabetic Patients

Seppo Lehto, MD; Leo Niskanen, MD; Matti Suhonen, MD; Tapani Rönnefao, MD; Pekka Saikku, MD; Markku Laakso, MD

**Background:** Chlamydia pneumoniae, a gram-negative bacterium, has been suggested to be a risk factor for atherosclerosis. Calcium is a well-known component of atherosclerotic plaques, but it is uncertain whether infectious agents play a role in the calcification process of the arteries.

**Patients:** To address this issue we investigated the association of Chlamydia antibodies with intimal arterial calcification as assessed by soft tissue radiograms from the thigh region of 1373 nondiabetic Finnish individuals aged 45 to 64 years.

**Results:** At baseline, radiologically detectable intimal calcification in femoral arteries was found in 172 (27%) of 638 men and 43 (6%) of 735 women \((P < .001\). The presence of intimal artery calcifications was strongly related to conventional atherosclerotic risk factors and to Chlamydia antibodies. In Cox regression analysis, association of Chlamydia antibodies with intimal artery calcification persisted after extensive adjustment for other cardiovascular risk factors \((P = .04\). A dose-response relationship was observed between Chlamydia antibodies and intimal femoral artery calcification \((P = .006\). The presence of intimal artery calcification was strongly associated with an increased risk of future coronary heart disease mortality \((P < .001\).

**Conclusion:** Chlamydia antibodies are strongly associated with intimal calcification of the femoral arteries.

Arch Intern Med. 2002;162:594-599

**C**

CHLAMYDIA PNEUMONIAE, a gram-negative obligate respiratory pathogen, has been suggested to be a possible trigger or even causative agent in the pathogenesis of atherosclerosis. This hypothesis was first presented by Finnish investigators, who showed that patients with coronary heart disease (CHD) had elevated IgG and IgA titers of antibodies and specific circulating immune complexes to Chlamydia. This result has been replicated in other populations, and, moreover, the presence of Chlamydia particles in atherosclerotic lesions in coronary and carotid arteries, the aorta, and abdominal aortic aneurysms has been directly demonstrated using polymerase chain reaction and immunohistochemical methods. These findings have led to eradication trials with antibiotics. In the rabbit model, Chlamydia infection accelerates the development of atherosclerosis, and treatment with azithromycin prevents it. Also, in human studies, azithromycin treatment may reduce the risk of cardiac events in patients with unstable angina or non-Q-wave myocardial infarction (MI) or in male survivors of MI.

Calcium has been a largely neglected, although well-known, component of atherosclerotic plaques. The presence of calcification in the coronary arteries as evaluated by electron-beam computed tomography has been suggested to be a sensitive, although not specific, marker of CHD that may yield information beyond traditional risk assessment. In the early phase, atherosclerotic lesions are composed mainly of lipids; from the third decade of life onward, the lesions are formed by progressive accumulation of intracellular and extracellular lipids and foam cells. From the fourth decade of life, atherosclerotic lesions may evolve primarily from fibrotic or calcific lesions. These lesions may further progress by surface defects, hemorrhage, or thrombus formation into complicated lesions and clinical manifestations. The early phases and progression of arterial calcification are poorly understood. In atherosclerotic plaques, calcium is found as hydroxyapatite, the form found also in the bone. Further similarities with calcium and bone metabo-
PATIENTS AND METHODS

STUDY POPULATION AT BASELINE

A random sample of nondiabetic individuals born and currently living in the Kuopio University Hospital district (eastern Finland) or in the Turku University Central Hospital district (western Finland) was taken from the population register containing all individuals aged 43 to 64 years. Of the 827 individuals in eastern Finland and 863 in western Finland originally eligible for the study, 651 in eastern Finland and 730 in western Finland participated in the study, giving participation rates of 79% and 85%, respectively. Two participants in eastern Finland and 6 in western Finland were excluded from the final analyses because diabetes mellitus was diagnosed at baseline. The final nondiabetic study population consisted of 649 individuals in eastern Finland and 724 in western Finland.

Comparison regarding some background variables was made between participants and nonparticipants by using the central register of the Social Insurance Institution. Participating and nonparticipating groups were similar with respect to clinical characteristics.

STUDY PROGRAM AND METHODS AT BASELINE EXAMINATION: 1982-1984

The study program was carried out during one outpatient visit to the Clinical Research Unit of the University of Kuopio or to the Rehabilitation Research Center of the Social Insurance Institution. The methods have been described in detail elsewhere.22 The visit included an interview on the history of chest pain symptoms suggestive of CHD, smoking, alcohol intake, physical activity, and the use of drugs. All medical records of participants who reported during the interview that they had been admitted to the hospital because of chest pain or symptoms suggestive of stroke were reviewed. Review of the medical records was performed by 2 of us (M.L. in Kuopio and T.R. in Turku) after careful standardization of the methods between the reviewers. The World Health Organization criteria for verified definite or possible MI based on chest pain symptoms, electrocardiographic changes, and enzyme determinations were used in the ascertainment of the diagnosis of previous MI.23

Blood pressure was measured with the patient in the sitting position after a 5-minute rest using a mercury sphygmomanometer and was read to the nearest 2 mm Hg. Patients were classified as having hypertension if they were receiving drug treatment for hypertension or if their systolic blood pressure was at least 160 mm Hg or their diastolic blood pressure was at least 95 mm Hg.

BIOCHEMICAL METHODS

All laboratory specimens were obtained at 8 AM, after a 12-hour fast. Fasting plasma glucose concentration was determined using the glucose oxidase method (Boehringer Mannheim, Mannheim, Germany). Serum lipid and lipoprotein levels were determined from fresh serum samples drawn after a 12-hour overnight fast. Serum total cholesterol and triglyceride levels were assayed using automated enzymatic methods (Boehringer). Serum high-density lipoprotein (HDL) cholesterol levels were determined enzymatically after precipitation of low-density lipoprotein (LDL) and very low-density lipoprotein cholesterols with dextran sulfate and magnesium chloride.24 The LDL cholesterol was calculated using the Friedewald formula as follows:

\[ \text{LDL Cholesterol} = \text{Total Cholesterol} - \text{HDL Cholesterol} - \left( \frac{0.45}{\text{Total Triglycerides}} \right) \]

In patients with a triglyceride value greater than 354 mg/dL (>4.0 mmol/L), the LDL cholesterol concentration was not calculated. Chlamydia IgG and IgA antibodies were determined from blood samples drawn during baseline examination. A simplified microimmunofluorescence modification with one spot was used.25 Antigen of the Kajaani 6 strain

Continued on next page
of *Chlamydia pneumoniae* was obtained from Labsystems Oy (Helsinki, Finland). Incubation for 4-fold serum dilutions was 1 hour. For IgG titrations, dilutions starting at 1:32 were used. For IgA titrations, the serum samples were absorbed by Gullsborg treatment (Gull Laboratories, Salt Lake City, Utah), and dilutions were started at 1:10. All titrations were read by the same person (P.S.) using dry magnification (×400) in a Leitz fluorescence microscope with a 100-W mercury vapor lamp. Participants were classified as having elevated titers for *Chlamydia* if the IgA titer for *Chlamydia* was 1/40 or greater and the IgG titer was 1/128 or greater, as has been shown previously.1

**RADIOLOGICAL METHODS**

Native soft tissue radiograms of the thigh were taken with the patient in a recumbent position. Radiological findings were analyzed by a radiologist (M.S.) in random order without knowledge of the *Chlamydia* antibody titers of the patient. The lower limb artery calcifications were divided according to the method of Lindbom28 into discrete plaque (intimal type) and uniform linear railroad track (medial type) calcifications. Grading of arterial calcifications was carried out separately on both sides by assessing the involvement of arterial trunks or branches. The extent of intimal and medial calcifications was originally graded as follows: 1 indicates none; 2, slight (calcifications just visible involving the arterial trunks or their branches of ≤5 cm long); 3, moderate (intermediate grade, neither grade 2 nor grade 4); or 4, marked (considerable calcification of ≥50% of the length of the arterial trunk with or without involvement of the arterial branches). For statistical purposes, intimal calcifications were divided into absent (grade 1) or present (grades 2-4), except in Figure 1, where they were graded as none (grade 1), moderate (grade 2 and grade 3), or severe (grade 4). The κ coefficients for intraobserver variation were 0.87 for intimal calcification and 0.88 for medial calcification.

**STATISTICAL METHODS**

Data analyses were performed using a statistical software program (SPSS/PC; SPSS Inc, Chicago, Ill). The results of continuous variables are given as mean±SE or percent, as appropriate. Differences between the groups were assessed using the χ² test or the 2-tailed t test for independent samples, when appropriate. The multivariate Cox regression model and Kaplan-Meier survival curves were used to investigate the association of cardiovascular risk factors with the incidence of fatal CHD events.

**COLLECTION OF FOLLOW-UP DATA**

In 1990, a postal questionnaire containing questions about hospitalization because of acute chest pain and symptoms suggesting stroke or lower limb amputation was sent to every surviving participant of the original study cohort. All medical records of participants who died between the baseline examination and December 31, 1989, or who reported in the questionnaire that they had been admitted to the hospital because of the aforementioned symptoms were reviewed. The World Health Organization criteria for definite or possible stroke based on a clinical syndrome consisting of neurological signs or symptoms persisting for longer than 24 hours were used to ascertain the diagnosis of stroke, as in the baseline study. The criteria for MI and stroke were identical to those in the baseline study. Copies of death certificates of patients who had died were obtained from the files of the Central Statistical Office of Finland. In the final classification of the causes of death, hospital and autopsy records were used, if available. The end point evaluated in this study was mortality from CHD (*International Classification of Diseases, Ninth Revision*, codes 410-414).29 The study was approved by the ethics committees of the University of Kuopio and the University of Turku.

The major findings of this large, population-based study were that the presence of chlamydia antibodies was associated in a dose-response fashion with the degree of intimal artery calcification and that this association was not explained by other cardiovascular risk factors. These findings suggest, but do not prove, that *Chlamydia* may play a fundamental role in the pathogenesis of calcification of atherosclerotic lesions.

In this study, native soft tissue radiographs were used to visualize artery calcifications. Separation of the intimal and medial forms of calcification is in most instances easily done.31 *Chlamydia* antibodies were associated with intimal artery calcifications and not with medial artery calcifications. The former type of calcifi-
lication represents obstructive atherosclerosis, whereas the latter is a nonobstructive calcification of the medial layer commonly associated with aging and diabetes mellitus.\(^{32,33}\) However, as an index of atherosclerosis, the radiological intimal artery calcifications are rather crude, and radiological examination is likely to underestimate the degree of atherosclerosis.\(^{34}\) However, this method is sensitive, cheap, readily available, and, as shown in this study, a strong predictor of CHD mortality.

*Chlamydia* antibody titers may decrease substantially within a few years after seroconversion and may increase with the occurrence of reinfection. This temporal variation implies that any association of vascular disease with antibody titers for *Chlamydia* measured only once is substantially weaker than associations of vascular disease with long-term antibody concentration or more direct evidence of persistent infection at the relevant anatomical site.\(^{35}\) Therefore, it is remarkable that in our study the severity of intimal artery calcification increased linearly with the occurrence of *Chlamydia* antibodies. This association is suggestive of a close association of these processes, although suggestions of causality must be viewed with great caution.

The mechanisms via which *Chlamydia* can increase the risk of atherosclerosis remain unclear. Potentially it may precipitate acute cardiovascular events (plaque rupture) or may increase the size of the atherosclerotic plaque. This association could be mediated, at least in part, by an indirect effect of an adverse pattern of known or potential cardiovascular risk factors. Indeed, *Chlamydia* is associated with an adverse profile of serum lipids and lipoproteins,\(^{36}\) coagulation factors, and oxidative metabolites.\(^{37}\) Furthermore, smoking is strongly associated with arterial calcification, and as smokers more frequently have *Chlamydia* antibodies,\(^{38}\) smoking could account for a significant proportion of this effect. The relationship between *Chlamydia* antibodies and arterial calcification was not particularly strong among smokers in our study but was most evident in nonsmokers. Therefore, in our study and some previous studies,\(^{3,4}\) the association of *Chlamydia* with atherosclerosis is not explained statistically by conventional risk factors. Other indirect mechanisms behind this link could be mediated by chronic inflammation and/or cross-reactive antibodies.\(^{35,39}\) However, there is also in vitro evidence for a more direct association because *Chlamydia* may infect and multiply in smooth muscle cells, macrophages, and endothelial cells,\(^{40}\) all of which may contribute to the formation of atherosclerotic plaques. Our findings that *Chlamydia* antibodies were associated with intimal calcification but not medial calcification are in accordance with the hypothesis that *Chlamydia* could be directly involved in the process of calcification.

Although the accumulation of smooth muscle cells is a hallmark of atherosclerosis, the frequency of replication of smooth muscle cells in atherosclerotic plaques is in fact rather low.\(^{20}\) Therefore, other processes, for ex-

![Figure 1. The presence of *Chlamydia pneumoniae* antibodies by the degree of intimal femoral artery calcification.](image_url)

### Table 1. Patient Characteristics and Cardiovascular Risk Factors in Relation to the Presence of Intimal Femoral Artery Calcification at Baseline*

<table>
<thead>
<tr>
<th>Intimal Femoral Artery Calcification</th>
<th>No</th>
<th>Yes</th>
<th>(P) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men/women, No.</td>
<td>466/692</td>
<td>172/43</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Age, y</td>
<td>54.1 ± 0.2</td>
<td>57.6 ± 0.3</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Body mass index, kg/m(^2)</td>
<td>26.8 ± 0.2</td>
<td>25.7 ± 0.5</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Previous myocardial infarction, %†</td>
<td>3.6</td>
<td>12.6</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Hypertension, %</td>
<td>31.9</td>
<td>35.8</td>
<td>.26</td>
</tr>
<tr>
<td>Smoking, %</td>
<td>15.1</td>
<td>44.7</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Insulin, µU/mL‡</td>
<td>12.0 ± 0.03</td>
<td>13.5 ± 0.01</td>
<td>.003</td>
</tr>
<tr>
<td>Cholesterol, mg/dL§</td>
<td>181 ± 2</td>
<td>189 ± 3</td>
<td>.04</td>
</tr>
<tr>
<td>Low-density lipoprotein</td>
<td>Total</td>
<td>181 ± 2</td>
<td>189 ± 3</td>
</tr>
<tr>
<td>High-density lipoprotein</td>
<td>58 ± 0.4</td>
<td>54 ± 1</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Total triglycerides, mg/dL¶</td>
<td>123 ± 2</td>
<td>146 ± 8</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>IgA antibodies ≥40 for <em>Chlamydia pneumoniae</em>, %</td>
<td>5.6</td>
<td>9.6</td>
<td>.01</td>
</tr>
<tr>
<td>IgG antibodies ≥128 for <em>Chlamydia pneumoniae</em>, %</td>
<td>6.2</td>
<td>11.2</td>
<td>.001</td>
</tr>
</tbody>
</table>

*Data are given as mean ± SE except where indicated otherwise.
†To convert insulin from microunits per milliliter to picomoles per liter, multiply microunits per milliliter by 6.945.
‡To convert cholesterol from milligrams per deciliter to millimoles per liter, multiply milligrams per deciliter by 0.02586.
§To convert triglycerides from milligrams per deciliter to millimoles per liter, multiply milligrams per deciliter by 0.01129.
\(\) Calculated.
Table 2. Adjusted Hazard Ratios for the Association of Chlamydia pneumoniae Antibodies With the Presence of Intimal Femoral Artery Calcification (Cox Regression Model)∗

<table>
<thead>
<tr>
<th>Adjustment for</th>
<th>Hazard Ratio (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, sex, area of residence, total cholesterol level, smoking status, hypertension</td>
<td>1.71 (1.02-2.17)</td>
<td>.03</td>
</tr>
<tr>
<td>Age, sex, area of residence, total cholesterol level, smoking status, hypertension, HDL cholesterol level, triglyceride level, body mass index</td>
<td>1.68 (1.01-1.87)</td>
<td>.04</td>
</tr>
</tbody>
</table>

∗CI indicates confidence interval; HDL, high-density lipoprotein. IgA antibodies ≥40 and IgG antibodies ≥128 for Chlamydia pneumoniae.

Figure 2. Association of Chlamydia pneumoniae antibodies with intimal artery calcification in relation to smoking status. Chlam+ indicates Chlamydia antibodies present; Chlam−, Chlamydia antibodies absent.

Figure 3. Kaplan-Meier estimates of the probability of death caused by coronary heart disease in participants with (Calc+) and without (Calc−) intimal femoral artery calcification according to the presence (Chlam+) or absence (Chlam−) of Chlamydia pneumoniae antibodies (P<.001 between the Calc−, Chlam− and Calc−, Chlam+ groups vs other groups).

not explain this association. Therefore, it is possible that Chlamydia may also play a role in the calcification process of atherosclerosis, a hitherto largely neglected component of this disorder.

Accepted for publication July 16, 2001.

This study was supported by grants from the Academy of Finland (Helsinki), the Finnish Heart Research Foundation (Helsinki), the Sigrid Juselius Foundation (Helsinki), and the Aarne and Aili Turunen Foundation (Kuopio).

Corresponding author and reprints: Markku Laakso, MD, Department of Medicine, University of Kuopio, PO Box 1777, SF-70210 Kuopio, Finland (e-mail: markku.laakso @kuh.fi).

REFERENCES


©2002 American Medical Association. All rights reserved.


